This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
by Zacks Equity Research
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
INCYPositive Net Change GSKPositive Net Change NVSPositive Net Change
biotechnology biotechs pharmaceuticals
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
by Zacks Equity Research
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
AZNPositive Net Change NVSPositive Net Change PFENo Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
by Ahan Chakraborty
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
by Kinjel Shah
PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
PFENo Net Change AZNPositive Net Change JNJPositive Net Change MRKPositive Net Change
pharmaceuticals
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
by Kinjel Shah
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
IRWDPositive Net Change RLMDNegative Net Change LRMRNegative Net Change CRDLNegative Net Change INDVNegative Net Change
pharmaceuticals
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
by Ekta Bagri
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
LQDANegative Net Change UTHRPositive Net Change INSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
by Kinjel Shah
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
LLYPositive Net Change NVSPositive Net Change JNJPositive Net Change ABBVPositive Net Change
pharmaceuticals
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
by Kanishka Das
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
MRKPositive Net Change AZNPositive Net Change RHHBYPositive Net Change BMYPositive Net Change
pharmaceuticals
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
BMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
by Zacks Equity Research
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
LQDANegative Net Change UTHRPositive Net Change INSMNegative Net Change
biotechnology biotechs medical pharmaceuticals